New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
14:26 EDTCYTKCytokinetics volatility elevated into trial data announcement
Cytokinetics April call option implied volatility is at 91, May is at 212, August is at 180, November is at 199; compared to its 26-week average of 151 according to Track Data, suggesting larger near term price movement into the tirasemtiv Phase IIb trial data likely to be announced at the American Academy of Neurology meeting in late April.
News For CYTK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
16:19 EDTCYTKCytokinetics sees initiating phase 3 tirasemtiv program in Q2
Cytokinetics (CYTK) expects to initiate a phase III clinical development program for tirasemtiv in patients with ALS in Q2. Cytokinetics expects to initiate a phase II trial of CK-2127107 in patients with SMA in 2H. Cytokinetics expects results from COSMIC-HF to be available in 2H. Cytokinetics expects to continue joint development activities in collaboration with Amgen (AMGN) directed to the potential advancement of omecamtiv mecarbil to phase III clinical development.
16:17 EDTCYTKCytokinetics reports Q1 EPS (23c), may not compare to consensus (12c)
Reports Q1 revenue $4.41M, may not compare to consensus $10.08M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use